Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Stock Now Rated “Hold” by Sell-Side Brokerages

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) has received a consensus rating of “Hold” from the six brokerages that are currently covering the firm, MarketBeat.com reports. Two analysts have rated the stock with a sell recommendation, one has assigned a hold recommendation and three have given a buy recommendation to the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $62.40.

Several research analysts have recently issued reports on SUPN shares. Cantor Fitzgerald upped their price target on shares of Supernus Pharmaceuticals from $63.00 to $67.00 and gave the stock an “overweight” rating in a report on Thursday, July 9th. Wall Street Zen cut Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, August 8th. Zacks Research downgraded Supernus Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research report on Monday, October 5th. Finally, Weiss Ratings restated a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a report on Monday, September 21st.

Supernus Pharmaceuticals Price Performance

SUPN stock opened at $37.88 on Tuesday. The stock has a market cap of $2.21 billion, a price-to-earnings ratio of -19.73, a P/E/G ratio of 0.80 and a beta of 0.55. The company has a 50 day simple moving average of $43.75 and a 200 day simple moving average of $46.40. Supernus Pharmaceuticals has a 1 year low of $37.54 and a 1 year high of $59.68.

Supernus Pharmaceuticals (NASDAQ:SUPN) last issued its earnings results on Monday, August 3rd. The specialty pharmaceutical company reported ($1.01) earnings per share for the quarter, missing analysts’ consensus estimates of $0.42 by ($1.43). Supernus Pharmaceuticals had a negative net margin of 13.23% and a positive return on equity of 11.13%. The company had revenue of $219.06 million during the quarter, compared to analyst estimates of $205.31 million. During the same quarter in the prior year, the business earned $0.40 EPS. The business’s quarterly revenue was up 32.4% on a year-over-year basis. On average, equities research analysts anticipate that Supernus Pharmaceuticals will post 2.05 EPS for the current fiscal year.

Institutional Investors Weigh In On Supernus Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in SUPN. Public Employees Retirement System of Ohio acquired a new stake in Supernus Pharmaceuticals in the second quarter valued at $25,000. Rockefeller Capital Management L.P. lifted its holdings in Supernus Pharmaceuticals by 354.8% during the 4th quarter. Rockefeller Capital Management L.P. now owns 846 shares of the specialty pharmaceutical company’s stock worth $42,000 after buying an additional 660 shares during the period. Global Retirement Partners LLC acquired a new position in Supernus Pharmaceuticals during the 2nd quarter worth about $64,000. Versant Capital Management Inc lifted its holdings in Supernus Pharmaceuticals by 47.2% during the 3rd quarter. Versant Capital Management Inc now owns 1,503 shares of the specialty pharmaceutical company’s stock worth $65,000 after buying an additional 482 shares during the period. Finally, Nykredit A S bought a new stake in shares of Supernus Pharmaceuticals in the 2nd quarter valued at about $110,000.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing and commercializing treatments for diseases of the central nervous system (CNS). The company’s portfolio has primarily addressed epilepsy, attention-deficit/hyperactivity disorder (ADHD), and other neurological conditions, with an emphasis on differentiated formulations and products designed to improve treatment convenience and patient outcomes.

Supernus markets Oxtellar XR (oxcarbazepine extended-release) for the treatment of partial-onset seizures and Trokendi XR (topiramate extended-release) for certain seizure disorders and the prevention of migraine headaches.